Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
BTK inhibitors
Pharma
AstraZeneca trumpets new Calquence combos in CLL
With the AMPLIFY trial win, the combination of Calquence, venetoclax and Gazyva may become the first triplet regimen in CLL.
Angus Liu
Jul 29, 2024 10:25am
AZ clinches early Calquence win in untreated MCL
May 2, 2024 10:24am
As Imbruvica fails, Brukinsa wins FDA nod in follicular lymphoma
Mar 7, 2024 4:08pm
BeiGene added 1,400 employees as key cancer drugs expand
Feb 26, 2024 11:03am
Lilly’s Jaypirca tipped to capture 60% of BTK leukemia market
Jan 22, 2024 11:59am
Lilly's Jaypirca blazes CLL trail with FDA approval
Dec 4, 2023 4:11am
